Clinical Supply Agreement to support phase II clinical trial: Cambridge, UK Friday, May 22, 2026, 18:00 Hrs [IST] 4basebio PLC, a company pioneering an enzymatically ...
May2026– 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation ...
Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial ...
Engage Bio’s Tethosome platform is designed to improve the potency, tolerability, and redosability of non-viral DNAAcquisition combines Engage’s innovative platform with Lilly’s broad genetic ...
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome ...
Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
RNA is the means of translating the genetic code embedded in DNA into proteins, which serve as enzymes, transporters, ...
The video argues that cancer is not one disease but hundreds, which is why curing it has been so difficult. It focuses on the ...
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting ...
Earlier this month, a cluster of severe acute respiratory illnesses aboard the Dutch-flagged cruise ship MV Hondius was reported to the World Health Organization (WHO). The infections have since been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results